Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by amritadaniqueon Oct 20, 2023 7:10am

84 Views

Post# 35692517

$BIXT: Transforming Healthcare with Innovative Solutions

Bioxytran, Inc. ($BIXT) is a pioneering force in healthcare, focused on combating hypoxia with innovative pharmaceutical solutions. Their robust market capitalization, exceeding $24.5 million, and 144 million+ outstanding shares indicate the company's growth potential. With a strong 30-day average volume of 161,816, there's a growing interest in their transformative treatments. The previous closing price of $0.1699 underscores their promise to advance medical science. Bioxytran, Inc. is on a mission to improve patient outcomes and create a healthier world.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter